Literature DB >> 22865309

Optical coherence tomography analysis of the stenting of saphenous vein graft (SOS) Xience V Study: use of the everolimus-eluting stent in saphenous vein graft lesions.

Aristotelis C Papayannis1, Tesfaldet T Michael, Dinara Yangirova, Abdul-Rahman Abdel-Karim, Julia Kohlhaas, Arif Mahmood, Tayo Addo, Donald Haagen, Lorenza Makke, Michele Roesle, Bavana Rangan, Subhash Banerjee, Emmanouil S Brilakis.   

Abstract

OBJECTIVES: The Stenting of Saphenous Grafts-Xience V (SOS-Xience V) trial prospectively examined the frequency of angiographic in-stent restenosis in saphenous vein graft (SVG) lesions 12 months after implantation of a Xience V everolimus-eluting stent (EES; Abbott Vascular). Optical coherence tomography (OCT) during follow-up angiography was added to the protocol after OCT was approved for clinical use in the United States.
METHODS: Forty patients with 40 SVG lesions were enrolled in the study, of whom 27 underwent 12-month coronary angiography and 12 (only 1 of whom had in-stent restenosis) also had follow-up OCT evaluation. OCT strut-level analysis was performed to determine the percentage of strut coverage, malapposition, strut protrusion, neointimal thickness, and the existence of thrombus.
RESULTS: Mean patient age was 67 ± 7 years, and 95% were men. A total of 2584 struts were evaluated by OCT. The percentages for uncovered, malapposed, and protruding struts were 4%, 9%, and 15%, respectively. The mean strut neointimal thickness was 0.094 ± 0.094 mm. Of the 12 stents analyzed, 4 (33%) showed full neointimal coverage, 2 (17%) had all the struts embedded, 7 (58%) had at least 1 malapposed strut, and 10 (83%) had at least 1 protruding strut. The mean difference between the stent area and the lumen area was 0.36 ± 1.6 mm². No thrombus was detected in the stented areas.
CONCLUSIONS: Use of EES in SVGs is associated with high rates of stent strut coverage and high malapposition rates at 12 months post implantation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22865309

Source DB:  PubMed          Journal:  J Invasive Cardiol        ISSN: 1042-3931            Impact factor:   2.022


  3 in total

1.  Rationale and design of the Drug-Eluting Stents vs Bare-Metal Stents in Saphenous Vein Graft Angioplasty (DIVA) Trial.

Authors:  Emmanouil S Brilakis; Subhash Banerjee; Robert Edson; Kendrick Shunk; Steven Goldman; David R Holmes; Deepak L Bhatt; Sunil V Rao; Mark W Smith; Mike Sather; Cindy Colling; Biswajit Kar; Lori Nielsen; Todd Conner; Todd Wagner; Bavana V Rangan; Beverly Ventura; Ying Lu; Mark Holodniy; Mei-Chiung Shih
Journal:  Clin Cardiol       Date:  2017-08-25       Impact factor: 2.882

2.  Saphenous vein graft interventions.

Authors:  Emmanouil S Brilakis; Michael Lee; Julinda Mehilli; Konstantinos Marmagkiolis; Josep Rodes-Cabau; Rajesh Sachdeva; Anna Kotsia; George Christopoulos; Bavana V Rangan; Atif Mohammed; Subhash Banerjee
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-05

3.  Bioresorbable vascular scaffolds in saphenous vein grafts (data from OCTOPUS registry).

Authors:  Tomasz Roleder; Wojciech Wanha; Grzegorz Smolka; Jacek Zimoch; Andrzej Ochała; Wojciech Wojakowski
Journal:  Postepy Kardiol Interwencyjnej       Date:  2015-01-12       Impact factor: 1.426

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.